Company Ampliphi Biosciences Corp Nyse
Equities
US03211P3010
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pathogen-specific Bacteriophage Therapeutics
100.0
%
| 6 | 100.0 % | 5 | 100.0 % | -17.77% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Australia
100.0
%
| 6 | 100.0 % | 5 | 100.0 % | -17.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 11/23/11 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 26/20/26 |
Bryan Kadotani
PRN | Corporate Officer/Principal | - | - |
Richard Rychlik
AUD | Comptroller/Controller/Auditor | 68 | 05/23/05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 12/20/12 | |
Joseph Patti
BRD | Director/Board Member | 60 | 09/19/09 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 01/21/01 |
Odysseas Kostas
BRD | Director/Board Member | 49 | 12/20/12 |
Robin Kramer
CHM | Chairman | 58 | 08/20/08 |
Todd Peterson
BRD | Director/Board Member | 66 | 10/19/10 |
Deborah Birx
CEO | Chief Executive Officer | 68 | 11/23/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,154,617 | 10,746,770 ( 29.72 %) | 0 | 29.72 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+51.85% | 5.79TCr | |
+41.42% | 4.03TCr | |
-5.25% | 3.99TCr | |
-5.16% | 2.85TCr | |
+12.79% | 2.64TCr | |
-20.18% | 1.93TCr | |
+30.88% | 1.24TCr | |
+0.61% | 1.22TCr | |
+25.06% | 1.22TCr |